Spero Therapeutics Inc (fra:2HA) Share Price

Company Profile

Business description
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Contact
675 Massachusetts Avenue
14th Floor
CambridgeMA02139
USA
T: +1 857 242-1600
E: [email protected]
https://www.sperotherapeutics.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
25

Recommended

Investors in cheap ASX share with a narrow moat enjoys a high yield, but there are risks investors should be aware of.

Morningstar | 28 September 2026

Trading at an 18% discount, this wide-moat stock is a rare find.

Malik Ahmed Khan, CFA | 22 September 2026

Discounted exit raises investor concerns.

Yingqi Tan, CFA | 21 September 2026

Index	Last price	Change	% Change
All Ordinaries	8,886.60	35.90	0.41%
CAC 40	8,091.95	13.47	0.17%
DAX 40	25,515.38	140.96	0.56%
Dow JONES (US)	51,481.51	347.11	-0.67%
FTSE 100	10,724.83	39.95	0.37%
HKSE	24,523.57	118.94	-0.48%
NASDAQ	26,820.38	248.34	-0.92%
Nikkei 225	65,481.27	396.35	-0.60%
NZX 50 Index	13,683.63	147.05	-1.06%
S&P 500	7,683.69	59.72	-0.77%
S&P/ASX 200	8,709.30	29.60	0.34%
SSE Composite Index	3,830.45	6.83	0.18%